Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Short term Debt (2016 - 2025)

Historic Short term Debt for Arrowhead Pharmaceuticals (ARWR) over the last 10 years, with Q4 2025 value amounting to $40.0 million.

  • Arrowhead Pharmaceuticals' Short term Debt rose 236153.85% to $40.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $40.0 million, marking a year-over-year increase of 236153.85%. This contributed to the annual value of $40.0 million for FY2025, which is N/A changed from last year.
  • As of Q4 2025, Arrowhead Pharmaceuticals' Short term Debt stood at $40.0 million, which was up 236153.85% from $40.0 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Short term Debt ranged from a high of $65.0 million in Q1 2025 and a low of $1.6 million during Q4 2024